Answers are grounded in this paper and cite their sources.
Preclinical study reveals development of a brain-penetrant TRPML1 agonist for Parkinson's disorders, suggesting therapeutic potential.
(i) To develop a brain-penetrant small molecule agonist for the lysosomal TRPML1 channel and, (ii) Perform preclinical studies supporting development in Parkinson’s-related disorders.
No takes yet. Share an insight, caveat, or question.
Murphy et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: